Ran Frenkel's most recent trade in Karyopharm Therapeutics Inc was a trade of 90,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 28, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 68,250 | 169,953 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Sale of securities on an exchange or to another person at price $ 10.24 per share. | 28 Feb 2022 | 1,663 | 168,290 (0%) | 0% | 10.2 | 17,025 | Common Stock |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Sale of securities on an exchange or to another person at price $ 12.12 per share. | 17 Feb 2022 | 2,929 | 101,703 (0%) | 0% | 12.1 | 35,509 | Common Stock |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 07 Feb 2022 | 1,991 | 104,632 (0%) | 0% | 9.9 | 19,635 | Common Stock |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 59,968 | 59,968 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 22,013 | 104,439 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 18 Feb 2021 | 2,887 | 46,126 (0%) | 0% | 14.8 | 42,818 | Common Stock |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 9,675 | 19,350 | - | - | Restricted Stock Units | |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 9,675 | 49,013 (0%) | 0% | - | Common Stock | |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Sale of securities on an exchange or to another person at price $ 15.52 per share. | 11 Feb 2021 | 2,046 | 39,338 (0%) | 0% | 15.5 | 31,752 | Common Stock |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 5,650 | 16,950 | - | - | Restricted Stock Units | |
| Karyopharm Therapeutics Inc | Ran Frenkel | EVP, Chief Dev. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 5,650 | 41,384 (0%) | 0% | - | Common Stock |